Compare Stocks: BHVN, SYRE, IONS, and IMVT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$12.35 -4.8%	$14.10	$7.48 ▼ $18.57	$1.87B	1.35	2.68 million shs	552,492 shs
IMVT Immunovant	$32.21 -3.1%	$39.03	$15.95 ▼ $45.42	$6.67B	0.84	1.51 million shs	357,250 shs
IONS Ionis Pharmaceuticals	$44.45 +2.2%	$53.69	$42.63 ▼ $86.74	$7.38B	0.38	2.64 million shs	544,503 shs
SYRE Spyre Therapeutics	$80.84 -12.8%	$95.57	$16.00 ▼ $110.18	$7.13B	3.1	1.11 million shs	2.12 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	+1.09%	-1.96%	-17.02%	-16.51%	-17.79%
IMVT Immunovant	-1.10%	-0.72%	-15.29%	-17.06%	+96.75%
IONS Ionis Pharmaceuticals	-0.09%	-4.54%	-25.12%	-49.61%	-37.09%
SYRE Spyre Therapeutics	-0.50%	+8.08%	+4.20%	-1.60%	+483.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$12.35 -4.8%	$14.10	$7.48 ▼ $18.57	$1.87B	1.35	2.68 million shs	552,492 shs
IMVT Immunovant	$32.21 -3.1%	$39.03	$15.95 ▼ $45.42	$6.67B	0.84	1.51 million shs	357,250 shs
IONS Ionis Pharmaceuticals	$44.45 +2.2%	$53.69	$42.63 ▼ $86.74	$7.38B	0.38	2.64 million shs	544,503 shs
SYRE Spyre Therapeutics	$80.84 -12.8%	$95.57	$16.00 ▼ $110.18	$7.13B	3.1	1.11 million shs	2.12 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	+1.09%	-1.96%	-17.02%	-16.51%	-17.79%
IMVT Immunovant	-1.10%	-0.72%	-15.29%	-17.06%	+96.75%
IONS Ionis Pharmaceuticals	-0.09%	-4.54%	-25.12%	-49.61%	-37.09%
SYRE Spyre Therapeutics	-0.50%	+8.08%	+4.20%	-1.60%	+483.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHVN Biohaven	2.59	Moderate Buy	$18.69	48.58% Upside
IMVT Immunovant	2.58	Moderate Buy	$44.00	35.05% Upside
IONS Ionis Pharmaceuticals	2.73	Moderate Buy	$89.20	100.87% Upside
SYRE Spyre Therapeutics	2.88	Moderate Buy	$109.71	33.89% Upside

Current Analyst Ratings Breakdown

Latest BHVN, SYRE, IONS, and IMVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	IMVT Immunovant	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/1/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$121.00
10/1/2026	SYRE Spyre Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$110.00
9/24/2026	IMVT Immunovant	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/24/2026	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Positive
9/24/2026	IONS Ionis Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$85.00
9/24/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$100.00
9/23/2026	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/22/2026	IONS Ionis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$76.00 ➝ $70.00
9/18/2026	BHVN Biohaven	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/15/2026	IONS Ionis Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$89.00 ➝ $80.00

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.39 per share	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
IONS Ionis Pharmaceuticals	$944M	7.82	N/A	N/A	$3.02 per share	14.70
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	$7.21 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHVN Biohaven	-$738.82M	-$4.64	N/A	N/A	N/A	N/A	-1,328.94%	-138.27%	11/9/2026 (Estimated)
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	11/9/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)

Latest BHVN, SYRE, IONS, and IMVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	SYRE Spyre Therapeutics	-$0.7778	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.91	-$0.1490	-$0.91	$0.49 million	N/A
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHVN Biohaven	21.23	4.73	4.73
IMVT Immunovant	N/A	7.27	7.27
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
SYRE Spyre Therapeutics	N/A	18.53	18.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHVN Biohaven	88.78%
IMVT Immunovant	47.08%
IONS Ionis Pharmaceuticals	93.86%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
BHVN Biohaven	13.80%
IMVT Immunovant	1.90%
IONS Ionis Pharmaceuticals	1.81%
SYRE Spyre Therapeutics	15.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHVN Biohaven	274	151.04 million	130.20 million	Optionable
IMVT Immunovant	315	206.55 million	202.63 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
SYRE Spyre Therapeutics	112	87.94 million	74.14 million	Optionable

BHVN, SYRE, IONS, and IMVT Headlines

Recent News About These Companies

Spyre Therapeutics (NASDAQ:SYRE) Stock Falls 12.7% - Should You Sell?

5 minutes ago | marketbeat.com

Spyre Therapeutics Prices $350 Mln Public Offering Of Shares

4 hours ago | rttnews.com

Spyre Therapeutics prices $350M public offering at $85 per share

4 hours ago | msn.com

Spyre Therapeutics Commences Public Offering of Common Stock

October 5 at 8:18 PM | finance.yahoo.com

Spyre Therapeutics stock falls on public offering launch

October 5 at 8:18 PM | finance.yahoo.com

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

October 5 at 8:13 PM | globenewswire.com

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

October 5 at 4:01 PM | globenewswire.com

Spyre Therapeutics Announces Grants of Inducement Awards - October 2, 2026

October 5 at 10:17 AM | biospace.comB

Wells Fargo Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)

October 4 at 11:15 PM | theglobeandmail.com

Spyre (NASDAQ: SYRE) legal chief trims stake in planned share sale

October 4 at 12:00 PM | defenseworld.netD

Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows Sells 7,500 Shares of Stock

October 3 at 6:08 AM | americanbankingnews.com

Spyre Therapeutics (NASDAQ:SYRE) Stock: Insider Scott Burrows Sells 7,500 Shares

October 3 at 5:37 AM | insidertrades.com

Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows Sells 17,500 Shares of Stock

October 3 at 5:23 AM | americanbankingnews.com

Spyre Therapeutics (NASDAQ:SYRE) Insider Heidy King-Jones Sells 28,933 Shares of Stock

October 3 at 5:23 AM | americanbankingnews.com

Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares of Stock

October 3 at 5:22 AM | americanbankingnews.com

Spyre Therapeutics (NASDAQ:SYRE) Earns "Buy" Rating from BTIG Research

October 3 at 2:36 AM | americanbankingnews.com

JPMorgan Chase & Co. Begins Coverage on Spyre Therapeutics (NASDAQ:SYRE)

October 3 at 1:54 AM | americanbankingnews.com

Spyre Therapeutics (NASDAQ:SYRE) Upgraded at Wall Street Zen

October 3 at 1:07 AM | americanbankingnews.com

Spyre Therapeutics (NASDAQ:SYRE) Stock Rating Raised to Hold at Wall Street Zen

October 3 at 1:05 AM | marketbeat.com

Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells $688,725.00 in Stock

October 2, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Stock: Insider Cameron Turtle Sells 15,000 Shares

October 2, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BHVN, SYRE, IONS, and IMVT Company Descriptions

Biohaven NYSE:BHVN

$12.35 -0.62 (-4.78%)

As of 12:04 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Immunovant NASDAQ:IMVT

$32.21 -1.04 (-3.12%)

As of 12:04 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Ionis Pharmaceuticals NASDAQ:IONS

$44.44 +0.95 (+2.17%)

As of 12:04 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Spyre Therapeutics NASDAQ:SYRE

$80.84 -11.88 (-12.82%)

As of 12:04 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BHVN, SYRE, IONS, and IMVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BHVN, SYRE, IONS, and IMVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BHVN, SYRE, IONS, and IMVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BHVN, SYRE, IONS, and IMVT Company Descriptions

Biohaven NYSE:BHVN

Immunovant NASDAQ:IMVT

Ionis Pharmaceuticals NASDAQ:IONS

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BHVN, SYRE, IONS, and IMVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BHVN, SYRE, IONS, and IMVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BHVN, SYRE, IONS, and IMVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BHVN, SYRE, IONS, and IMVT Company Descriptions

Biohaven NYSE:BHVN

Immunovant NASDAQ:IMVT

Ionis Pharmaceuticals NASDAQ:IONS

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools